A new COVID-19 treatment for PRE-Exposure Prophylaxis is available at Kettering Health. EVUSHELD™ (tixagevimab/cilgavimab) will be available for providers to order on Thursday February 17, 2022.
EVUSHELDTM (tixagevimab co-packaged with cilgavimab) is authorized for use under an emergency use authorization (EUA) for the pre-exposure prophylaxis of COVID-19 in adults:
- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and
- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
- EVUSHELD™ is NOT authorized for the following:
- For treatment of COVID-19
- For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
- Pre-exposure Prophylaxis with EVUSHELD™ is NOT a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
- In individuals who have received a COVID-19 vaccine, EVUSHELD™ should be administered at least two weeks after vaccination.
Patient must have one (1) of the following risk factors:
- Patients who are within 1 year of receiving B-cell depleting therapies (e.g. riTUXimab, ocrelizumab, ofatumumab, ibritumomab tiuxetan, obinutuzumab, belimumab)
- Patients receiving ibrutinib, acalabrutinib, zanubrutinib
- Chimeric antigen receptor T-cell recipients (CAR T-cell Therapy) (Idecabtagene Vicleucel, Brexucabtagene Autoleucel, Axicabtagene Ciloleucel)
- Hematopoietic cell transplant recipients
- Graft-versus-host disease
- Hematologic malignancy on active therapy
- Solid organ transplant recipients
- Congenital or Acquired Immunodeficiency (hypogammaglobulinemia requiring IVIG administration, CVID, X-linked agammaglobulinemia, severe selective IgA deficiency, severe specific Ab deficiency, chronic granulomatous disease, SCID, etc.)
- HIV patients with CD4 count < 50 cells/mm3
Patients who meet the above criteria will be eligible to receive EVUSHELD™ monoclonal antibody injection.
All eligible patients will be scheduled and treated at Kettering Health Washington Township Infusion Center (Southview Outpatient Infusion Center).
The EVUSHELD referral can be found by searching “Evusheld” or under REF115165 in EPIC.
Non-EPIC users can use the attached order form.